Author: Sokal Etienne
Publisher: Informa Healthcare
ISSN: 1465-6566
Source: Expert Opinion on Pharmacotherapy, Vol.3, Iss.3, 2002-03, pp. : 329-339
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Cost-Effectiveness Analysis of Lamivudine for the Treatment of Chronic Hepatitis B
By Crowley S.J.
PharmacoEconomics, Vol. 17, Iss. 5, 2000-05 ,pp. :
Lamivudine for chronic hepatitis B - dosage in paediatric patients
Inpharma, Vol. 1, Iss. 1231, 2000-01 ,pp. :
Long-term lamivudine beneficial in chronic hepatitis B
Inpharma, Vol. 1, Iss. 1249, 2000-01 ,pp. :
Sustained response to lamivudine in chronic hepatitis B
Inpharma, Vol. 1, Iss. 1387, 2003-01 ,pp. :
Peginterferon- -2a superior to lamivudine for chronic hepatitis B
Inpharma, Vol. 1, Iss. 1456, 2004-01 ,pp. :